other material
confidence high
sentiment positive
materiality 0.60
Monopar reports tumor reduction in Phase 1b camsirubicin trial for advanced soft tissue sarcoma at CTOS
Monopar Therapeutics
- 14 patients enrolled across 5 dose cohorts; 9 of 14 had stable disease per RECIST 1.1.
- All patients in cohorts 4 and 5 achieved stable disease; 3 most recent showed ~20% tumor reduction.
- One patient with unresectable cancer became eligible for resection after tumor reduction and underwent successful surgery.
- No dose-limiting toxicity observed; MTD not yet reached; one LVEF decrease in medically complex patient is being monitored.